Kailera Therapeutics is trading 4.1% down today at $19.84 as investors continue to reassess Phase 3 data for its oral GLP-1 obesity pill, KAI-7535.
- Sentiment is being pressured by reports of high rates of nausea and vomiting in China-based trials, which have overshadowed the drug meeting its primary efficacy endpoints.
- The stock is extending a pullback from last week as biotech analysts and media coverage focus on the drug's tolerability profile relative to competitors.